Vertex Pharmaceuticals earned the fund’s spotlight as a long-term bet. Vertex remains the undisputed leader in the cystic fibrosis market, creating a near $10 billion franchise with its CFTR ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 13.32%. Currently, Vertex Pharmaceuticals has a ...

Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 0.31%, and its shares lost 5.40% of their value over the last 52 weeks.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B cell-driven diseases in Japan and South Korea. Vertex pockets upfront cash, ...

BOSTON (WHDH) - Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent solution for insulin. They say it has been tested on 12 ...